Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
For researchers working in preclinical and laboratory contexts, the July 2026 decision does not change availability of research-grade material
Dysesthesia The TRIUMPH-4 trial data revealed a notable safety signal: dysesthesia (abnormal sensations like tingling, burning, or numbness) was reported in 8.8% of participants on the 9 mg dose and 20.9% on the 12 mg dose of retatrutide
Nationwide shipping with temperature-controlled packaging tailored to peptide stability requirements
Why Choose B12 Injections Instead of Tablets
US$ 22.73
US$ 24.79
US$ 26.72
